Press release
Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight
Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the GvHD market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The GvHD market forecast anticipates a CAGR of 8.2% through 2034 from USD 1.3 billion in 2023. Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.
Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report also analyzes historical and projected GvHD epidemiology, segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.
DelveInsight estimates approximately 52K Graft Versus Host Disease cases in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.
Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2025 to 2034. Current GvHD therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.
Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.
DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.
Unlock which emerging Graft Versus Host Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.
Furthermore, in March 2025, Signal12 Pharmaceuticals secured FDA alignment for their Phase 3 trial of Pro-ocular, a novel drop-free therapy for ocular graft-versus-host disease, following successful Phase 2 results showing sustained improvements in corneal staining and symptom scores. These recent developments indicate a positive momentum in the GvHD treatment market.
Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.
Table of Contents
1. Key Insights
2. Report Introduction
3. GvHD Market Overview at a Glance
4. Executive Summary
5. Key Events
6. GvHD Background and Overview
7. Methodology
8. GvHD Epidemiology and Patient Population
9. GvHDPatient Journey
10. GvHD Marketed Drugs
11. GvHD Emerging Drugs
12. GvHD - 7MM Market Analysis
13. KOL Views
14. GvHD Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Graft versus host disease (GvHD) Pipeline Insight [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, and Amgen among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-set-to-expand-at-82-cagr-through-2034-driven-by-a-robust-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft Versus Host Disease Market Set to Expand at 8.2% CAGR Through 2034, Driven by a Robust Pipeline | DelveInsight here
News-ID: 4078720 • Views: …
More Releases from ABNewswire
Studio Khora and the Architecture of American Relevance
From Biscayne Bay to the national imagination, Studio Khora crafts sculptural homes that merge art, AI, and sustainability-redefining what contemporary American architecture can be.
In American architecture, style has often been mistaken for identity. Yet at a time when our landscapes are changing-ecologically, technologically, and culturally-Studio Khora offers something more profound: a response.
Their homes, born from the heat and humidity of Miami, don't just reflect their setting; they interrogate it. They…
Becky Grindle Unveils a Riveting Story of Awakening and Truth in Information War
For readers seeking a powerful journey through political awakening and personal courage, Becky Grindle delivers an eye-opening account with her new book Information War: Awakening to a New Reality . Through raw and passionate storytelling, Becky shares her personal experiences during one of the most pivotal decades in American history.
Information War is not just a story - it's a call to awareness. Starting in 2015, Becky describes how an ordinary…
New German Shepherd Puppies Available For Reservation In Wonder Lake IL
Mittelwest German Shepherds in Wonder Lake, IL, offers exceptional new litters now available for reservation. Raised with care, these AKC-registered German Shepherd puppies combine health, temperament, and beauty. View all current litters and reserve a companion today.
Wonder Lake, IL - Mittelwest German Shepherds, an American Kennel Club (AKC) Breeder of Merit, is thrilled to announce the availability of new exceptional litters. Families and individuals looking for world-class German Shepherd puppies…
'Soul Speaks' By Jennifer Grana: A powerful collection of poetry that journeys t …
Through her debut writing efforts, Jennifer Grana published a powerful collection of poems titled Soul Speaks [https://a.co/d/aZUPuoK], which presents the intense truth of life's battles and progress toward recovery. Through stirring images and genuine confession, Grana guides readers from sickness to mental health issues through loss toward personal enlightenment so they can honor the transformative capacity of fighting on.
About the Book:
The poetry collection exceeds literature's definition because it delves…
More Releases for GvHD
Graft Versus Host Disease (GVHD) Treatment Market Poised for 7.5 % Growth, Set t …
"How Are the key drivers contributing to the expansion of the graft versus host disease (gvhd) treatment market?
The increasing number of hematological disorders is expected to spur the growth of the graft versus host disease (GVHD) treatment market. Hematological disorders affect blood components and are linked to lifestyle factors, genetics, and environmental toxins. GVHD treatments are effective for patients with blood cancers such as leukemia and lymphoma. For example, in…
Graft Versus Host Disease (GVHD) Treatment Global Market Analysis, Trends, Growt …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Graft Versus Host Disease (GVHD) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.82…
Acute Graft Versus Host Disease [GvHD] Treatment Industry To Witness Robust Expa …
The global Acute Graft Versus Host Disease [GvHD] Treatment market is estimated to attain a valuation of US$ 634 Mn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.6% during the forecast period, 2022-2031.
The key objective of the TMR report is to offer a complete assessment of the global market…
Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2022
Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD - which develops within 100 days of transplantation and chronic GvHD - which develops after 100…
Graft Versus Host Disease (GvHD) Market Expected to Expand at a Steady 2022-2028 …
Coherent Market Insights have added a new research study on Title Graft Versus Host Disease (GvHD) Market, Global Outlook and Forecast 2022-2028 with detailed information & Key Players Such as Gvhd market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., and Mesoblast Ltd. The Study provides in-depth comprehensive analysis includes Clear Market definitions, classifications, manufacturing processes, cost structures, development policies and plans. The…
Graft Versus Host Disease (GvHD) Market: Taking New Steps to Meet the Challenges …
Coherent Market Insights has released a new research study on the "Graft Versus Host Disease (GvHD) Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Graft Versus Host Disease (GvHD) Market Report detailed information and overview highlight the most recent trends in various regions. Leading market participants will benefit from the trading insights provided in this report. The Graft Versus…
